Connect with us

News

FluroTech Announces Filing of Patent Applications With Respect to Its Proprietary Diagnostic Test Method and Pandemic Defense Platform

CALGARY, Alberta, Oct. 22, 2020 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF), (“FluroTech” or “the Company”) is pleased to announce that FluroTest LLC (“FluroTest”), a company in which the Company has an equity interest, has filed patent applications with the United States Patent and Trademark Office with respect to certain aspects of its proprietary test method and […]

The post FluroTech Announces Filing of Patent Applications With Respect to Its Proprietary Diagnostic Test Method and Pandemic Defense Platform appeared first on CannabisFN.

Republished by Plato

Published

on



Ryan Allway

October 26th, 2020

News, Top News


CALGARY, Alberta, Oct. 22, 2020 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF), (“FluroTech” or “the Company”) is pleased to announce that FluroTest LLC (“FluroTest”), a company in which the Company has an equity interest, has filed patent applications with the United States Patent and Trademark Office with respect to certain aspects of its proprietary test method and “Pandemic Defense Platform” (the “Platform”).

FluroTest’s patent pending Platform will be offered both on a turn-key basis to third parties seeking to operate their own testing solution as well as on a “testing as a service” offering to be operated by FluroTest, serving communities seeking a total solution for surge-scale, high-volume testing services necessary to safely open their environments at scale. The Platform will be available for deployment in Latin America immediately, and will be available for deployment in the United States, Canada and Europe, pending regulatory approval.

By combining and leveraging the disciplines of robotics automation, biochemistry (antibody labeling and binding), fluorescence detection and cloud computing, FluroTest believes it is creating the first pandemic defense platform of its kind. FluroTest anticipates that a single platform installation could potentially serve over 3,000 test takers per hour with digitally verifiable results transmitted to a secure, managed, HIPAA compliant cloud environment and be available to the test taker’s mobile device within approximately 5 minutes. The platform is intended to make it possible to test up to 100% of a specific community population every 4 to 7 days at a low cost to the test taker and with a high value to the communities served by the platform.

“Our Platform solution solves a significant problem we are all facing. Assuring the safety and security of people and building trust in environments where large numbers of people are present requires an entire system rather than a single test. We have purpose-built that entire system. Our team is proud to offer this Platform solution to accomplish this goal,” said Bill Phelan, CEO of FluroTest.

The FluroTest Platform is a saliva-based, point of collection diagnostic immunoassay designed for accurate, digitally verifiable results, delivered with high throughput capacity, which are transmitted to a secure, managed, cloud environment compliant with the standards for privacy of individually identifiable health information as promulgated in the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”).

Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device are still in the early stages of research and development and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus. The Platform is currently pending FDA approval. In addition, FluroTest requires additional capital in the near-term to further the development and deployment of its testing device and will be seeking equity investors and is exploring strategic partnerships in connection with the same.

FluroTest believes its Platform can benefit organizations serving large, concentrated populations and bearing significant pandemic risk, forcing them to incur consequential business disruptions and closures. Examples include, but are not limited to: colleges and universities, hospitals & large healthcare complexes, athletic stadiums & large performance venues, corporate campus environments, large office buildings & complexes, shopping malls and centers, retail working warehouses, factories, food processing plants, airlines, as well as any public transportation hub such as subway entrances and airport terminals.

About FluroTech (TSXV: TEST) (OTCQB: FLURF)

FluroTech’s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples for specific applications. Using technology that was first developed at the University of Calgary, FluroTech has created a two-part solution comprised of its CompleTest™ platform technology and consumable testing kits. Its accuracy has been independently validated. FluroTech continues to develop additional applications for the CompleTestTM platform technology. To learn more, visit FluroTech.com

About FluroTest LLC

FluroTest was firmed pursuant to a strategic agreement in principle between FluroTech, Alberta BioPhotonics Inc. (a related party to FluroTech with directors, officers and shareholders in common) and Albany Medical College. See the Company’s press releases dated April 16, 2020, April 28, 2020 and September 8, 2020 for additional information regarding FluroTest.

FluroTest is seeking additional capital in the near-term and will also be exploring strategic partnerships with manufacturing and distribution companies to advance the deployment of the new test that’s being developed. To learn more, visit FluroTest.com

Contact Information

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the formation of FluroTest and the capital structure thereof, how FluroTest’s Platform technology will be offered, the deployment of the Platform technology and the locations and timing in respect thereof, the ability of the Platform technology to test large numbers of sample in a short period of time and the accuracy of such testing, the low cost of testing using the Platform technology and the large benefits to be realized from using such technology, the ability to transmit test results to a secure, managed, HIPAA compliant cloud environment and deliver such results to test takers in a short period of time, the significant benefits of the Platform technology to communities and organizations and the need for financing of FluroTest in the near term and the formation of strategic partnerships for the deployment and distribution of the technology. The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, as well as the ability to develop and deploy the Platform technology as described herein in a timely manner and to obtain the financing required in connection with the same, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Actual results may vary from the forward-looking information in this news release due to certain material risk factors described in the Corporation’s Annual Information Form under the heading “Risk Factors” and the failure to develop and deploy the Platform technology as contemplated herein in a timely manner or at all, the risk that competitors will develop a similar or superior testing platform, the technology not having the anticipated testing benefits, the inability of FluroTest to obtain the necessary financing to achieve its purpose on satisfactory terms or at all, the failure to form strategic partnerships necessary to deploy and distribute the technology. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive.

The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Source: https://www.cannabisfn.com/flurotech-announces-filing-of-patent-applications-with-respect-to-its-proprietary-diagnostic-test-method-and-pandemic-defense-platform/

News

California: 27% of menopausal women use Cannabis to Manage Menopause Symptoms

  Every year, more than 2 million women reach menopause, while 27 million go through the throes of menopause. Defined as the…

The post California: 27% of menopausal women use Cannabis to Manage Menopause Symptoms first appeared on CBD.CI CBD Living.

Republished by Plato

Published

on

Every year, more than 2 million women reach menopause, while 27 million go through the throes of menopause. Defined as the end of a woman’s menstrual cycle, menopausal women experience a natural decline in reproductive function with common symptoms such as hot flashes, night sweats, and mood disorders. Cannabis appears to be a natural solution available to relieve these symptoms.

How cannabis affects menopause 

Researchers associated with the San Francisco VA Medical Center interviewed 232 women (average age 56) living in Northern California and participated in the Midlife Veterans Health Survey, focusing on their management of menopause. This study is available by clicking here.

More than half of them reported embarrassing symptoms such as hot flashes and night sweats (54%), insomnia (27%), and genitourinary symptoms (69%).

  • Approximately 27% of those sampled reported using or currently using cannabis to manage their symptoms.
  • Another 10% of participants expressed interest in trying cannabis to manage menopausal symptoms in the future. More surprisingly, the survey found that women were more likely to use cannabis than traditional menopause therapy such as hormone treatment:
  • Only 19% reported using a more traditional type of menopausal symptom management such as hormone therapy.

Results that prove the place of cannabis in natural alternatives 

These results suggest that using cannabis to manage menopausal symptoms may be relatively common,” said Carolyn Gibson, lead author of the study.

However, we don’t know whether cannabis use is safe or effective for the management of menopausal symptoms or whether women discuss these decisions with their health care providers – particularly in IL, where cannabis is considered an illegal substance under federal guidelines”.

Cannabis use was most often reported by women with hot flashes and night sweats, who represented more than half of those surveyed. About one-quarter of women reported insomnia, while 69% had frequent genitourinary symptoms.

Given the relatively high rate of cannabis use among women in this cohort, scientists and others would be well advised to further explore its safety, efficacy, and prevalence in postmenopausal women.

The researchers agreed with this sentiment, concluding that, while promising, the results of the small sample size required further investigation.

California: 27% of menopausal women use Cannabis to Manage Menopause Symptoms
Article Name
California: 27% of menopausal women use Cannabis to Manage Menopause Symptoms
Description
Defined as the end of a woman’s menstrual cycle, menopausal women experience common symptoms such as hot flashes, night sweats, and mood disorders. Cannabis appears to be a natural solution available to relieve these symptoms.
Publisher Name
Publisher Logo

What’s your reaction?

Source: https://www.cbd.ci/health/california-27-of-menopausal-women-use-cannabis-to-manage-menopause-symptoms/

Continue Reading

News

Zoro celebrates three years of continuous growth

Avatar

Published

on

Zoro celebrates three years of continuous growth

Zoro, UK supplier of fasteners, tools, and equipment to businesses within the engineering sector, is celebrating its third year of continuous growth with a team twice the size and an increased product range to that it started with.

Since 2017, Zoro has gone from strength to strength, with plans to increase staff by another quarter within the next year. The number of products Zoro has sold has also doubled to 300,000 items of PPE, tools, fasteners and equipment, including big name brands. Since January 2020 alone, the company has launched over 97,000 new products.

Zoro UK is daughter company to Fortune 500 company Grainger Global, which was founded in 1927, and has more than 3.2 million businesses and institutions that purchase maintenance, repair and operations (MRO) products. Zoro supplies PPE and equipment to more than 126,000 companies in the engineering, automotive, aerospace, rail, marine and construction markets across the UK.

Chris Matenaers, marketing director at Zoro UK, said: “With around 19% of the UK’s workforce employed in the engineering sector, it is essential that companies have a reliable source of quality equipment, tools and, most importantly, PPE.”

Throughout 2020, despite being a challenging year for many businesses, the Zoro Category Management Team have been able to increase the number of suppliers by ten percent to overcome supply chain issues.

Matenaers believes one of the key reasons for strong and steady growth, apart from competitive pricing and a strong product range, is the flexible trade accounts.

“With office-based teams currently working from home, our multi-user accounts allow for easy collaboration for teams to order the supplies they need. We understand how important next-day delivery and reliable customer service is and we are striving to keep up with demand.”

Zoro’s Business Accounts offers multi-user access, a feature developed for home working. All purchases made by users on the business account will contribute towards the company’s tiered pricing discounts scheme. Other features also include order subscription, introduced to reduce admin, easy-share quotations and multi-user accounts with capped spending.

https://www.zoro.co.uk

Tags

Share This Article

Subscribe to our FREE Newsletter

Related Articles

Most recent Articles

Source: https://www.aero-mag.com/zoro-celebrates-three-years-of-continuous-growth/

Continue Reading

News

Will Donald Trump gratify cannabis prisoners before leaving the White House?

  On Wednesday, some celebrities, republican leaders, and civil rights activists delivered a letter to President Trump appealing for pardons or reparations…

The post Will Donald Trump gratify cannabis prisoners before leaving the White House? first appeared on CBD.CI CBD Living.

Republished by Plato

Published

on

On Wednesday, some celebrities, republican leaders, and civil rights activists delivered a letter to President Trump appealing for pardons or reparations of federal marijuana prisoners for nonviolent cannabis-related crimes.

The letter states that the signatories “firmly believe that justice requires the exercise of executive clemency in these cases. “It is accompanied by a specific list of 24 people who are currently behind bars for cannabis-related offenses, many of whom are serving life sentences.

Weldon Angelos, who was himself sentenced to a mandatory minimum sentence for cannabis before a court reduced his sentence and released him, had already submitted a draft of the letter to the White House in March.

You have expressed support for the right of states to enforce their cannabis laws, especially for medical purposes,” wrote the signatories, including former NBA star Kevin Garnett. “And while there are several proposals before Congress to finally end the ban on cannabis, they tend to lack any real relief for those serving time for selling cannabis.

Given the timidity of this bill, the impasse in Congress, and the imperative of freedom, clemency is the right tool to resolve this problem,” he said. You and you alone have the power to call for the great hypocrisy of previous administrations. While cannabis has become a thriving legal market and has enriched many, your predecessors ignored those serving long federal sentences for doing the same thing.

Among the more than 50 signatories to the news, the letter is Alice Johnson, who appeared at the Republican National Convention and whose story was featured in pro-Trump ads after her drug sentence was overturned by the president.

Legislators from the Republican states of Kansas, Maine, and Missouri also signed, as did actor Danny Trejo, New Haven, Missouri Police Chief Danny Trejo, and former New Mexico Governor and presidential candidate Gary Johnson. They were joined by representatives of associations such as #cut50, Marijuana Policy Project, and Law Enforcement Action Partnership.

To date, during his administration, Trump has granted 27 pardons and 11 commutations. The signatories of this letter expect to see an increase in inclemency from the Executive Board in the coming weeks, as is the case in the last weeks of a presidency.

It is ridiculous that we currently have a billionaire in the cannabis industry, but let’s keep some people in jail for doing the same thing. This is just another example of a useless and destructive criminal justice system,” he said in a press release. I am confident that President Trump will strongly consider correcting some of the most egregious sentences we have brought to his attention.

He is the first president in modern history to commute several sentences during his first years in office,” he said. Traditionally, pardons and commutations take place at the end of a presidency, so this model reassures us that we will get justice for some of them.

No one knows, of course, how Trump will react to the demand for a series of cannabis-specific clemency measures.

Will Donald Trump gratify cannabis prisoners before leaving the White House?
Article Name
Will Donald Trump gratify cannabis prisoners before leaving the White House?
Description
On Wednesday, some celebrities, republican leaders, and civil rights activists delivered a letter to President Trump appealing for pardons or reparations of federal marijuana prisoners for nonviolent cannabis-related crimes.
Publisher Name
Publisher Logo

What’s your reaction?

Source: https://www.cbd.ci/news/will-donald-trump-gratify-cannabis-prisoners-before-leaving-the-white-house/

Continue Reading
CBD2 days ago

CBD News: CBD court ruling brings additional support in Germany for access

Heartland4 days ago

Lebanon Legalized Medical Cannabis, 1st in Arab World

Heartland4 days ago

Lebanon Legalized Medical Cannabis, 1st in Arab World

Heartland4 days ago

Lebanon Legalized Medical Cannabis, 1st in Arab World

Heartland5 days ago

Mounce: Hemp in Mexico and Texas: Pot Luck?

CBD1 day ago

GreenheartCBD Founder Paul Walsh named to the All-Ireland Business All Star List

Metal3 days ago

RINL subsidiary BSLC seeks to make dolomite supplies to other steel mills

Heartland4 days ago

CBD4 days ago

What Is CBD: The Complete Beginner’s Guide

Heartland5 days ago

Heartland5 days ago

Material2 days ago

Gamma radiation modified the optical, electrical, and antibacterial characterization of CuONPs doped in Polyethylene Oxide/Polyvinyl Alcohol

Heartland3 days ago

REVIEW: High Five Duo

Material2 days ago

Fabrication and characterization of nanostructured zinc oxide on printed microcontact electrode for piezoelectric applications

Heartland5 days ago

Material5 days ago

Structural analysis and magnetic characterization of ternary alloys (Co–Fe–Ni) synthesized by mechanical alloying

Manufacturing4 days ago

Building Fundamentals of Manufacturing

Heartland5 days ago

CBD for IBS? M/28/NY

Heartland5 days ago

Material5 days ago

PtOx-TiO2 anatase nanomaterials for photocatalytic reformation of methanol to hydrogen: effect of TiO2 morphology

Heartland4 days ago

CBD Full Spectrum Distillate

Uncategorized3 days ago

Did Joe Biden and Kamala Harris Just Pull A Fast One On The Cannabis Industry?

Heartland5 days ago

Material5 days ago

Synthesis and photocatalytic investigation of ZnFe2O4 in the degradation of organic dyes under visible light

Heartland5 days ago

This is what 58 looks like: Mother-of-four says daily bathing rituals, CBD cream and menopause …

Heartland5 days ago

Less Indiana hemp went to pot in 2020

Heartland5 days ago

I’m sure this has been asked before but I can’t seem to find a consensus. What is the best brand/product to take for strictly sleep. Are there any specific sleeping blends out there?

Heartland5 days ago

Heartland4 days ago

Heartland4 days ago

Trending

A Cloud Nine Capital Entity Copyright © 2020 – All Rights Reserved Proudly Made in America